After Hours Summary: INFN +13.3%, FB +12.2%, FLEX +10.4%, QCOM +2.5%, NSR -23.0%, CTXS -4.6% following earnings/guidance
* After Hours Gainers:
Companies trading higher in after hours in reaction to earnings: INFN +13.3%, FB +12.2%, ININ +10.6%, FLEX +10.4%, CNQR +7%, NOW +5.4%, CSII +5.4%, MKSI +4.8%, FTNT +4.4%, QCOM +2.5%, LRCX +2.4%, QLGC +2.3%, TCBK +1.2%, PRXL +0.8%, CMO +0.8%, IVAC +0.5%
Companies trading higher in after hours in reaction to news:
- IO +9.8% (announced that it has increased its ownership interest in OceanGeo, a geophysical company specializing in multicomponent ocean bottom seismic acquisition; ION now owns 70% of OceanGeo), - TWTR +6.0% (trading higher following strong quarterly results from Facebook), - NLST +5.6% (announced that it has filed motions to add two additional patents to the lawsuits against the recently announced ULLtraDIMM memory module from Diablo Technologies and Smart Storage Systems), - GERN +5.1% (announced public offering of common stock, size not disclosed), - GOOG +2.6% (confirmed Lenovo (LNVGY) is acquiring Motorola Mobility), - NOG +2.5% (announced 4Q2013 production is expected to average ~ 13,900 barrels of oil equivalent (Boe) per day, up 28% y/y), - GPOR +2.1% (announced retirement of CEO James Palm), - MPO +2.0% (provided operation update and preliminary 2014 production and capital guidance; sees Q4 adjusted EBITDA of $115-120 mln), - ARP +1.2% (increased quarterly distribution ~4% to $0.58 from $0.56 per unit)
* After Hours Losers:
Companies trading lower in after hours in reaction to earnings: NSR -23%, INVN -7.3%, TSCO -5.9%, CAVM -4.8%, ELY -4.7%, CTXS -4.6%, BVSN -4%, MLNX -3.3%, TTEK -2.8%, KEX -2.3%, SYMC -2.1%, BRKL -1.6%, QTM -1.6%, FBHS -1.4%, LVS -1.3%, QGEN -0.2%
Companies trading lower in after hours in reaction to news:
- KBIO -35.5% (reported top-line data for Phase 2 study of KB003 in severe asthma; while the study showed that KB003 was generally safe and well tolerated, it did not meet its primary clinical endpoint of improvement in FEV1 (a measurement of pulmonary function) compared to placebo in the overall study population), - NSR -23.0% (provided update on local number portability administrator selection process; co was notified that its October 2013 proposal would not be considered), - IDIX -5.1% (confirmed negative decision by the USPTO Trial and Appeal Board in the first patent interference case with Gilead), - PBYI -0.6% (filed for $115 mln common stock offering)